Sun Pharmaceutical Industries, Inc.
Clinical trials sponsored by Sun Pharmaceutical Industries, Inc., explained in plain language.
Large Indian pharmaceutical company manufacturing generic and specialty drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New light therapy could zap precancerous arm spots Results expected Jan 2027 (estimated)
- New Light-Activated gel aims to clear precancerous skin spots Results expected Jan 2027 (estimated)
- Hair loss drug shows promise in Long-Term trial for alopecia areata Results expected May 2027 (estimated)
-
Can a generic cream match Brand-Name rosacea treatments?
Disease control CompletedThis trial tests whether a generic ivermectin cream works as well as two brand-name versions for treating moderate to severe facial rosacea. Adults with the condition apply the cream once daily for 84 days. Researchers compare changes in inflammatory lesions and check safety agai…
Phase 1 • Sponsor: Sun Pharmaceutical Industries, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Generic acne gel put to the test in large trial
Disease control CompletedThis completed Phase 1 trial compared a generic tretinoin gel (0.04%) to the brand-name RETIN-A MICRO for treating acne vulgaris. Over 1,000 participants aged 12 to 40 with mild to moderate acne applied the gel daily for 12 weeks. The goal was to see if the generic version works …
Phase 1 • Sponsor: Sun Pharmaceutical Industries, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Hair loss drug shows promise in Long-Term trial
Disease control CompletedThis study tested the long-term safety and effectiveness of a drug called CTP-543 in 407 adults with moderate to severe alopecia areata, a condition that causes patchy or complete hair loss. Participants had already completed 24 weeks of treatment in a previous trial. The goal wa…
Phase 3 • Sponsor: Sun Pharmaceutical Industries, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Psoriasis cream showdown: new formula vs. approved treatment
Symptom relief CompletedThis study compared a new tapinarof cream to an already-approved one (Vtama®) for treating plaque psoriasis, a skin condition causing red, scaly patches. 575 adults with mild to moderate psoriasis used one of the creams or a placebo for a set time. The goal was to see if the new …
Phase 1 • Sponsor: Sun Pharmaceutical Industries, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC